Neuren PharmaceuticalsASX:NEU -1.09%54 EBITDA Margin % is 30.60% as of Dec. 2025, which is 23% below its 10-year median of 39.64. GuruFocus rates ASX:NEU with a GF Score™ of 54/100 and a GF Value™ of A$6.08 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Neuren Pharmaceuticals ranks better than 90.48% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neuren Pharmaceuticals EBITDA Margin % Related Terms
Neuren Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neuren Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NEU vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a EBITDA Margin % of 30.60% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuren Pharmaceuticals and its competitors. This is 23% below median its historical median of 39.64. According to the industry distribution chart, Neuren Pharmaceuticals ranks #90 out of 945 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Neuren Pharmaceuticals' EBITDA Margin % too high?
Neuren Pharmaceuticals' current EBITDA Margin % of 30.60% is 23% below median its 10-year median of 39.64. Based on the distribution chart, Neuren Pharmaceuticals ranks #90 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #90 out of 945 companies for EBITDA Margin %. This places Neuren Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current EBITDA Margin % is 30.60%, which is 23% below median its own 10-year median of 39.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$6.08, compared to a current price of A$12.76 — trading 109.9% above its estimated fair value. The current EBITDA Margin % is 30.60%, which is 23% below median its 10-year median of 39.64. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current EBITDA Margin % is 30.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$12.76 is trading 109.9% above its estimated GF Value™ of A$6.08.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
EBITDA Margin %: 30.60% (23% below median its 10-year median of 39.64)
GF Value™: A$6.08 vs. price of A$12.76 (109.9% above fair value)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score
Get the complete analysis for ASX:NEU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
